Payment overview · 2025
General Payments
$1,256.66
59 reported records · 17 companies
Healthcare provider profile · identity verified
Tanveer Aslam, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DYERSBURG, TN · NPI 1043239965
Verified facts
What the public records show
CMS Open Payments records show Tanveer Aslam, MD received $1,256.66 in general payments during 2025 across 59 reported records.
Novo Nordisk Inc accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Kerendia, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $206.53 | 16.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.77 | 15.8% | 7 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $163.15 | 13.0% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $150.75 | 12.0% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $119.65 | 9.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.14 | 5.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $62.80 | 5.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $46.93 | 3.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.32 | 3.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.09 | 3.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.64 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.14 | 2.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.10 | 1.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.55 | 1.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.35 | 1.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.27 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.48 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,256.66 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.53 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $183.58 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $163.15 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $150.75 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.27 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $119.65 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $116.73 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $109.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $62.80 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.76 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.42 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.14 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $27.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 154 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
150 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
154 | 41 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1454 | 197 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1210 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 1047 | 134 |
| Furosemide | Furosemide | 944 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 789 | 105 |
| Potassium Chloride | Potassium Chloride | 776 | 90 |
| Buspirone Hcl | Buspirone Hcl | 756 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 670 | 79 |
| Trazodone Hcl | Trazodone Hcl | 594 | 76 |
| Meloxicam | Meloxicam | 571 | 110 |
| Eliquis | Apixaban | 563 | 55 |
| Lisinopril | Lisinopril | 543 | 62 |
| Losartan Potassium | Losartan Potassium | 539 | 64 |
| Mirtazapine | Mirtazapine | 530 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 509 | 71 |
| Carvedilol | Carvedilol | 500 | 56 |
| Divalproex Sodium | Divalproex Sodium | 493 | 35 |
| Sertraline Hcl | Sertraline Hcl | 493 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 483 | 52 |
| Famotidine | Famotidine | 455 | 75 |
| Metformin Hcl | Metformin Hcl | 431 | 70 |
| Risperidone | Risperidone | 371 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 359 | 39 |
| Levetiracetam | Levetiracetam | 355 | 25 |
| Montelukast Sodium | Montelukast Sodium | 317 | 82 |
| Memantine Hcl | Memantine Hcl | 312 | 36 |
| Jardiance | Empagliflozin | 306 | 20 |
| Allopurinol | Allopurinol | 300 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 300 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 296 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 284 | 41 |
| Paroxetine Hcl | Paroxetine Hcl | 279 | 23 |
| Prednisone | Prednisone | 272 | 123 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 269 | 79 |
| Donepezil Hcl | Donepezil Hcl | 261 | 46 |
| Omeprazole | Omeprazole | 259 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 62 |
| Lamotrigine | Lamotrigine | 246 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 65 |
| Simvastatin | Simvastatin | 225 | 35 |
| Spironolactone | Spironolactone | 213 | 34 |
| Ezetimibe | Ezetimibe | 201 | 54 |
| Benztropine Mesylate | Benztropine Mesylate | 194 | 12 |
| Baclofen | Baclofen | 192 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 189 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 176 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 175 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 167 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 165 | 65 |
| Mounjaro | Tirzepatide | 163 | 23 |
| Cilostazol | Cilostazol | 160 | 39 |
| Atenolol | Atenolol | 159 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 156 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 154 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 153 | 33 |
| Primidone | Primidone | 153 | 15 |
| Linzess | Linaclotide | 150 | 29 |
| Desloratadine | Desloratadine | 146 | 54 |
| Amiodarone Hcl | Amiodarone Hcl | 141 | 13 |
| Farxiga | Dapagliflozin Propanediol | 139 | 25 |
| Celecoxib | Celecoxib | 137 | 41 |
| Glimepiride | Glimepiride | 137 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 34 |
| Glyxambi | Empagliflozin/Linagliptin | 128 | 21 |
| Gabapentin | Gabapentin | 127 | 41 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 126 | 20 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 125 | 18 |
| Valsartan | Valsartan | 123 | 31 |
| Tradjenta | Linagliptin | 122 | 15 |
| Lansoprazole | Lansoprazole | 120 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 118 | suppressed |
| Ozempic | Semaglutide | 118 | 20 |
| Topiramate | Topiramate | 115 | 20 |
| Aripiprazole | Aripiprazole | 107 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 54 |
| Oxybutynin Chloride | Oxybutynin Chloride | 104 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 31 |
| Haloperidol | Haloperidol | 100 | 14 |
| Midodrine Hcl | Midodrine Hcl | 100 | 14 |
| Lactulose | Lactulose | 96 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 14 |
| Azithromycin | Azithromycin | 94 | 75 |
| Olanzapine | Olanzapine | 94 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 92 | 13 |
| Oxcarbazepine | Oxcarbazepine | 92 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 16 |
| Januvia | Sitagliptin Phosphate | 89 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 89 | 70 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 39 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 88 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 86 | 18 |
| Lovastatin | Lovastatin | 83 | 17 |
| Propranolol Hcl | Propranolol Hcl | 81 | suppressed |
| Repatha Sureclick | Evolocumab | 81 | 11 |
| Myrbetriq | Mirabegron | 80 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 80 | suppressed |
| Pregabalin | Pregabalin | 79 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 78 | 22 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 78 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 77 | suppressed |
| Ibuprofen | Ibuprofen | 76 | 35 |
| Nabumetone | Nabumetone | 75 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 67 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 66 | 32 |
| Acarbose | Acarbose | 65 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 65 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 24 |
| Rexulti | Brexpiprazole | 63 | suppressed |
| Fenofibrate | Fenofibrate | 62 | suppressed |
| Metronidazole | Metronidazole | 62 | 39 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 48 |
| Sucralfate | Sucralfate | 61 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 60 | 15 |
| Levofloxacin | Levofloxacin | 60 | 48 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 59 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 13 |
| Cephalexin | Cephalexin | 56 | 41 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 56 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 55 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 13 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 13 |
| Colestipol Hcl | Colestipol Hcl | 52 | 11 |
| Irbesartan | Irbesartan | 52 | 15 |
| Bupropion Xl | Bupropion Hcl | 51 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 14 |
| Fluconazole | Fluconazole | 49 | 32 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 47 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 45 | 11 |
| Rivastigmine | Rivastigmine | 45 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 42 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 26 |
| Latanoprost | Latanoprost | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Bumetanide | Bumetanide | 39 | 17 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Austedo | Deutetrabenazine | 38 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 38 | 27 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 38 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 17 |
| Effer-K | Potassium Bicarbonate/Cit Ac | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | 16 |
| Mupirocin | Mupirocin | 36 | 22 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Vraylar | Cariprazine Hcl | 36 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 35 | suppressed |
| Gemtesa | Vibegron | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Metolazone | Metolazone | 34 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Zonisamide | Zonisamide | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Nystatin | Nystatin | 32 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Ssd | Silver Sulfadiazine | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | 14 |
| Insulin Aspart | Insulin Aspart | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 22 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 23 |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Nystop | Nystatin | 23 | 11 |
| Rybelsus | Semaglutide | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Phenytoin | Phenytoin | 20 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 13 | suppressed |
| Acetylcysteine | Acetylcysteine | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,256.66 · 59 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JOURNAVX, Kerendia, OTEZLA, Ohtuvayre, Ozempic, PROLIA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UZEDY, VYEPTI, YUPELRI | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error